CDKN2B

CDKN2B

A gene on chromosome 9p21 that encodes a member of the INK4 family of cyclin-dependent kinase inhibitors, which form a complex with CDK4 or CDK6, preventing activation of CDK kinases and thus acting as cell growth regulators by controlling cell cycle progression through G1. CDKN2B expression is dramatically induced by TGF beta, suggesting a role in TGF-beta-induced growth inhibition.
References in periodicals archive ?
3 which contained CDKN2A and CDKN2B genes, and they found that deletion of 6q21 ( PRDM1 ) was associated with shorter OS.
Como ejemplo de esto estan los estudios en Chile, de los genes APAF1, ASSP1, p73 y FHIT,p15, p16, ESR1, IGSF4, SOCS1(9); en Colombia, de los genes RARB y DAPK;CDKN2B y DBC1(10);en Brasil, del gen CDKN2B (p15) (11) y en Espana de CDH1, p73, p16, p15, p57, NES-1, DKK-3, CDH13, p14, TMS-1, Apaf-1, DAPK, Parkin, LATS-1(12).
Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
Frequent loss of chromosome 9, homozygous involving CDKN2A/p14ARF/ CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
Teupser, "Expression of Chr9p21 genes CDKN2B (p15INK4b), CDKN2A (p16INK4a, p14ARF) and MTAP in human atherosclerotic plaque," Atherosclerosis, vol.
Using carefully designed DNA probes, we were able to specifically detect the 8 possible epialleles of a 3-CpG cluster on the promoter of the CDKN2B (p15) tumor-suppressor gene, for which heterogeneous methylation has been implicated as a driver in a variety of cancers (4, 5, 7-9).
Although the tumor suppressor genes CDKN2A and CDKN2B are located in this region, the specific gene(s) and/or biological mechanism underlying this risk association is still unknown.
The CDKN2A and CDKN2B genes are cyclin-dependent kinase inhibitors which regulate cell cycle and belong to a family of genes that have been implicated in the pathogenesis of atherosclerosis through their role in transforming growth factor-[beta]-induced growth inhibition.
3 risk-allele locus spans 50-60 kb and is in linkage disequilibrium (LD) with the 3' end of CDKN2B, encoding the cyclin-dependent kinase inhibitor tumor suppressor pl5INK4B, with weaker LD extending through CDKN2B to CDKN2A, which encodes another tumor suppressor pl6INK4B.
3) This region contains the coding sequence for two cyclin-dependent kinase inhibitors, CDKN2A and CDKN2B, which play an important role in the regulation of the cell cycle and have been implicated in the pathogenesis of atherosclerosis, as well as for MTAP, a methylthioadenosine phosphorylase enzyme important in polyamine metabolism and the salvage of adenine and methionine.